SLC5A2 and diabetes mellitus: With the chronic use of SGLT2 inhibitors, increased β-hydroxybutyrate is effectively utilized in oxidized/damaged tubular cells by increasing ATP production [36] and suppressing the mechanistic target of rapamycin complex 1 signaling, which causes podocyte damage under diabetes [37].